

Switch to Etravirine from Efavirenz  
**SWITCH-EE STUDY**

# Switch from Efavirenz to Etravirine

## SWITCH-EE: Design

### Study Design: SWITCH-EE

- **Background:** Randomized, double-blind, crossover study comparing the safety and efficacy of etravirine with efavirenz
- **Inclusion Criteria (n = 58)**
  - Age  $\geq 18$  years
  - On EFV-containing ART regimen for  $\geq 3$  months
  - HIV RNA  $< 50$  copies/mL for  $\geq 3$  months
- **Treatment Arms**
  - EFV 600 mg daily + NRTI backbone x 6 weeks, then switch EFV to ETR
  - ETR 400 mg daily + NRTI backbone x 6 weeks, then switch ETR to EFV


*"EFV First" Group*  
**EFV 600 mg QD + NRTIs, then  
switch EFV to ETR**  
(n = 28)

*"ETR First" Group*  
**ETR 400 mg QD + NRTIs, then  
switch ETR to EFV**  
(n = 30)

# Switch from Efavirenz to Etravirine

## SWITCH-EE: Result

Week 12: Treatment Preference




Source: Nyugen A, et al. AIDS. 2011;25:57-63.

# Switch from Efavirenz to Etravirine

## SWITCH-EE: Result


Week 12: Treatment Preference, with Significant Order Effect



# Switch from Efavirenz to Etravirine

## SWITCH-EE: Result

Week 12: Change in Plasma Lipids from Baseline



# Switch from Efavirenz to Etravirine

## SWITCH-EE: Conclusions

**Conclusion:** “After substitution of efavirenz by etravirine, patients did not express a significant preference for etravirine. There was no measurable effect on neuropsychiatric symptoms and sleep. Cholesterol decreased.”

# Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.*

